This strategic shift began June 1, when Lixte announced its intent to transform into an AI-driven energy infrastructure business. While the company is currently seeking a partner to offload its existing medical technology and drug development assets, investors reacted skeptically to the transition. The stock remains up 63% for the year despite the recent sell-off.
In section Market Quotes
Lixte Biotechnology Pivots to Energy Storage Amid Stock Slide
Shares of Lixte Biotechnology tumbled 12% to $6.41 during Friday trading after the cancer-drug developer unveiled plans to pivot into the energy sector. The company intends to acquire Nomad Transportable Power Systems and rebrand itself as Nomad Power Solutions, marking a sharp departure from its historical pharmaceutical focus.
Lixte has not disclosed the financial terms of the Nomad acquisition. The target company, which specializes in mobile utility-grade battery storage, reported a 175% revenue increase in 2025. Lixte emphasizes that Nomad’s mobile systems provide a logistical advantage over traditional, permanent battery energy storage projects, which often face development delays spanning two to five years.
Comments (0)
No comments yet. Be the first!